• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Prothena moves for­ward with lay­offs; Aldeyra re­sub­mits dry eye drug to FDA

4 weeks ago
News Briefing

Min­eralys gets a mid-stage win in hy­per­ten­sion pa­tients with poor re­nal func­tion

4 weeks ago
R&D

Dyne piv­ots on pri­ma­ry end­point, de­lays fil­ing for DM1 drug

4 weeks ago
R&D

Iso­mor­phic to open US of­fice in Cam­bridge, hires ex-Re­lay CMO

4 weeks ago
People
AI

Lil­ly to bol­ster gene edit­ing pipeline, buy­ing Verve for up to $1.3B

4 weeks ago
Deals

Im­muneer­ing says MEK pill beats stan­dard of care in first-line pan­cre­at­ic can­cer

4 weeks ago
R&D

Fired vac­cine ad­vi­sors de­fend ACIP’s work, in­de­pen­dence in joint ed­i­to­r­i­al

4 weeks ago
R&D
Pharma

Pur­due opi­oid set­tle­ment gets back­ing from 55 at­tor­neys gen­er­al

4 weeks ago
Pharma
Law

Eli Lil­ly makes all Zep­bound dos­es avail­able in sin­gle-dose vials 

4 weeks ago
Pharma
Marketing

What's com­ing in five years? FDA chief points to uni­ver­sal flu vac­cine, new ap­proval path­way

4 weeks ago
FDA+

Ab­b­Vie’s can­cer drug fails Phase 3 com­bo study to treat oth­er bone mar­row dis­eases

4 weeks ago
R&D
Pharma

Roche moves ahead with Phase 3 Parkin­son’s study de­spite mixed tri­al re­sults

4 weeks ago
R&D

In­cyte’s promis­ing throm­bo­cythemia drug; Cres­cent Bio­phar­ma rais­es $200M in PIPE

4 weeks ago
News Briefing

NextCure inks ADC deal with Shang­hai drug­mak­er

4 weeks ago
Deals
China

Help us find 2025's best biotech star­tups: Nom­i­na­tions are open for End­points 11

4 weeks ago
Startups
Editor's note

Up­dat­ed: Sage's roller coast­er ends in $561M ac­qui­si­tion by Su­per­nus

4 weeks ago
Deals

Lil­ly posts en­cour­ag­ing ear­ly-stage weight loss da­ta on amylin can­di­date

4 weeks ago
R&D

Gilead, Ar­cel­lx con­tin­ue to spot­light safe­ty of mul­ti­ple myelo­ma cell ther­a­py

4 weeks ago
R&D
Cell/Gene Tx

Sarep­ta halts Duchenne gene ther­a­py in some pa­tients af­ter sec­ond death

4 weeks ago
R&D
Cell/Gene Tx

RFK re­moves all ACIP mem­bers, names new ones; Na­tion­al Re­silience to close six sites; Deals and fi­nanc­ing re­cap of ...

4 weeks ago
Weekly

For­mer CEO Anne Wo­j­ci­c­ki wins bid for 23andMe

4 weeks ago
Deals
Health Tech

KalVista says FDA de­layed de­ci­sion on HAE drug, cit­ing ‘heavy work­load’ 

4 weeks ago
Pharma
FDA+

FDA's on­col­o­gy ad­comm to re­view GSK's Blenrep re­launch plans

4 weeks ago
Pharma
FDA+

An­oth­er round of con­sol­i­da­tion is com­ing, FDA com­mis­sion­er tells staff

4 weeks ago
People
FDA+
First page Previous page 6789101112 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times